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Background: Although the common cold is generally mild and self-limiting, it is a leading cause of consultations
with doctors and missed days from school and work. In light of its favorable effects of relieving symptoms and minimal
side-effects, Traditional Chinese Medicine (TCM) has been widely used to treat the common cold. However, there is
a lack of robust evidence to support the clinical utility of such a treatment. This study is designed to evaluate the
efficacy and safety of Gantong Granules compared with placebo in patients with the common cold with wind-heat
syndrome (CCWHS).
Methods/Design: This is a multicenter, phase IIb, double-blind, placebo-controlled and randomized clinical trial. A total
of 240 patients will be recruited, from 5 centers across China and randomly assigned to the high-dose group,
medium-dose group, low-dose group or placebo control group in a 1:1:1:1 ratio. All subjects will receive the treatment
for 3 to 5 days, followed by a 7-day follow-up period. The primary outcome is the duration of all symptoms. Secondary
outcomes include the duration of primary symptoms and each symptom, time to fever relief and time to fever
clearance, change in TCM symptom score, and change in Symptom and Sign Score.
Discussion: This trial will provide high-quality evidence on the efficacy and safety of Gantong Granules in
treating CCWHS, and help to optimize the dose selection for a phase III clinical trial.
Trial registration: The registration number is ChiCTR-TRC-14004255, which was assigned by the Chinese Clinical
Trial Registry on 12 February 2014.
Keywords: Common cold, Wind-heat syndrome, Gantong Granules, Randomized controlled trial, Traditional
Chinese medicineBackground
The common cold has been with humanity since an-
tiquity. It is the most widespread illness in humans with
the average adult getting two to four colds a year and
the average child getting six to eight colds [1]. Although
the common cold is generally mild and self-limiting, it
is the leading cause of consultations with doctors and
days missed annually from school and work [2]. There are* Correspondence: maobing@medmail.com.cn
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unless otherwise stated.more than 200 viruses associated with the common cold
and the rhinovirus is the most common cause [3]. The
symptoms of the common cold can vary considerably
between different viruses and often include a tickle or
sore throat, sneezing, runny nose, nasal congestion,
coughing, mild fever and general malaise [1,4]. So far,
there is no proven intervention for treating or preventing
the common cold. Thus, current treatments mainly focus
on symptom relief. Few available therapies, including zinc,
vitamin C, Echinacea, garlic, antihistamines, intranasal
ipratropium, corticosteroids, antibiotics, and so on [5-14],
are recommended due to ineffectiveness, questionable
benefit, or adverse effects. Traditional Chinese Medicineis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cine that has benefited numerous people worldwide. In
fact, in China and many other countries, a number of
patients prefer TCM treatment rather than Western medi-
cine to treat the common cold. As the most important
component of TCM, Chinese medicinal herbs are mainly
derived from plants and usually incorporate one or more
herbs to treat a disease. Based on TCM syndrome differ-
entiation, the common cold can be divided into the wind-
cold, wind-heat or summer-heat dampness syndrome
according to its symptoms and TCM signs, such as fever,
headache, fatigue, aversion to cold, sneezing, nasal conges-
tion, nasal discharge, nausea, vomiting, tongue proper,
tongue coating and condition of pulse [15]. The common
cold with wind-heat syndrome (CCWHS) is the most
common type and occurs in all seasons; it is primarily
characterized by fever, mild aversion to cold, sore throat,
nasal congestion and discharge. According to the treat-
ment principles of TCM, CCWHS should be treated by
clearing heat and releasing stagnated Lung-Qi.
Gantong Granules is a novel Chinese patent medicine
that is manufactured by Beikelian Pharmaceutical & Tech-
nology Co., Ltd, Shenzhen, China. It is mainly composed
of Chaihu (Radix bupleuri), Gegen (Radix puerariae), Niu-
bangzi (Fructus arctii), Bohe (Herba menthae), Banlangen
(Radix isatidis), Chuanbeimu (Bulbus fritillariae unibrac-
teatae), Qianhu (Radix peucedani) and Jiegeng (Radix pla-
tycodi). All of these ingredients have been approved by the
China Food and Drug Administration (CFDA). Gantong
Granules has been proven effective in treating CCWHS
based on clinical experiences in the Affiliated Hospital of
Changchun College of TCM. Preclinical pharmacologic
experiments showed that Gantong Granules had the ef-
fects of clearing heat, relieving pain, reducing inflamma-
tion and alleviating cough. A second-stage clinical trial
also demonstrated that it could improve symptoms of
CCWHS. In addition, no evidence of an adverse or toxic
effect has been found in toxicological studies.
In accordance with the Drug Administration Law
of the People’s Republic of China and Good Clinical
Practice (GCP) issued by CFDA, this phase IIb clinical
trial is well-designed to evaluate the efficacy and safety
of Gantong Granules compared with placebo in patients
with CCWHS. Additionally, it is expected to find a dose-
effect relationship and provide useful evidence for a
Phase III clinical program.
Methods/Design
Design
This study is a multicenter, phase IIb, double-blind, pla-
cebo-controlled and randomized clinical trial. This trial
has been authorized by the CFDA (Approval Number
2004 L04586) and registered with the Chinese Clinical
Trial Registry (ChiCTR-TRC-14004255). In addition, theprotocol is conducted in accordance with the Declaration
of Helsinki (2008) and the Good Clinical Practice Guide-
lines [16]. The study is financially supported by Beikelian
Pharmaceutical & Technology Co., Ltd, Shenzhen, China,
which had or will have no role in the study design,
analysis, data interpretation or decision to submit results.
Across the five trial centers, all investigators are appropri-
ately qualified by training and experiences to conduct and
supervise the trial. All patients have to provide their writ-
ten informed consent prior to study entry. The flow chart
of this study is shown in Figure 1.
Ethics
The trial protocol has been approved by five local ethics
committees, including the Clinical Trials and Biomedical
Ethics Committee of West China Hospital of Sichuan Uni-
versity (Number TCM-2013-08), the Clinical Trials and
Biomedical Ethics Committee of the Affiliated Hospital of
Chengdu University of TCM, the Clinical Trials and Bio-
medical Ethics Committee of the First Hospital of Hunan
University of TCM, the Clinical Trials and Biomedical
Ethics Committee of the Affiliated Hospital of Nanjing
University of TCM, and the Clinical Trials and Biomedical
Ethics Committee of the Affiliated Hospital of Jangxi Uni-
versity of TCM. Research assistants will introduce the trial
to potential subjects, and give them information sheets
about the trial. All eligible patients have to give their
signed informed consent before enrollment. The privacy
of all participants will be protected. Personal medical
records will be taken by investigators and inspectors, who
will promise to keep that secret. Regulatory authorities
have the right to examine the test data. Data anonymity
will be used in process of data management. Finally, the
data of all subjects will be kept centrally.
Recruitment
We plan to recruit patients through advertisements and
recommendations. A total of 240 patients will be re-
cruited in this trial at the following 5 hospitals across
China: 1) West China Hospital of Sichuan University,
2) the Affiliated Hospital of Chengdu University of TCM,
3) The First Hospital of Hunan University of TCM, 4) the
Affiliated Hospital of Nanjing University of TCM, 5) the
Affiliated Hospital of Jangxi University of TCM. Forty-
eight patients will be recruited at each center.
Randomization and blinding
Using a stratified block randomization method, 240 eli-
gible patients will be randomly allocated to the high-dose
group, medium-dose group, low-dose group or placebo
control group in a 1:1:1:1 ratio. The randomization se-
quence will be generated using the PRCO PLAN function
of the analysis system of SAS software (SAS, Cary, NC,
USA). The randomization lists will be concealed in a
Figure 1 Study flow chart.
Table 1 Traditional Chinese Medicine (TCM) diagnostic
criteria
Category Symptoms and signs
Primary symptoms Fever, mild aversion to cold, sore throat
Secondary
symptoms




Red tongue and thin yellow tongue coating
Signs for the pulse Floating and rapid pulse
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kept by the leader and the sponsor of the study. Treat-
ment allocation will be blinded to the participants and in-
vestigators throughout the course of the study. The
emergency envelope will be saved in each center, and only
be opened for medical emergency purposes.
Diagnostic criteria for the common cold
The diagnosis in Western medicine is established accord-
ing to Practice of Internal Medicine (2009, Version 13)
[17] and Consensus on the Diagnosis and Treatment of
Common Cold by Respiratory Branch of Chinese Medical
Association and Emergency Branch of Chinese Medical As-
sociation [18]. Patients should have typical clinical mani-
festations of the common cold, such as sneezing, nasal
discharge, nasal congestion, and/or sore throat, as well as
excluding other diseases.
The TCM diagnosis of CCWHS is based on the Guide-
lines for Clinical Research of New Chinese Medicine [19].
The TCM diagnostic criteria for CCWHS are listed in
Table 1. To be diagnosed with CCWHS, patients should
have all the primary symptoms and at least three of the
secondary symptoms, as well as the TCM signs for the
tongue and pulse.
Inclusion criteria
 Diagnosis of common cold according to Western
medicine
 Diagnosis of CCWHS according to TCM
 Aged between 18 and 65 years Presenting within 48 hours after symptom onset
 Willing to participate and sign the informed consent
Exclusion criteria
 Patients with influenza, acute bacterial sinusitis, allergic
rhinitis, streptococcal pharyngitis and herpangina
 Patients with imaging manifestations of pulmonary
infection
 Patients with serious primary diseases of the
cardiovascular, pulmonary, kidney, and hematological
system
 Patients with liver function levels (such as alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), serum total bilirubin (STB), alkaline phosphatase
(ALP), and/orγ-glutamyl transpeptidase (γ-GT)) 1.5
times higher than the upper limit of normal, abnormal
serum creatinine, positive urine protein qualitative test,
white blood cell count < 3.0 × 109/L or > 10.0 × 109/L,
and/or neutrophil percentage > 80%.
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symptoms
 Patients with a body temperature higher than 38.5°C
 Pregnant women, lactating women, or women who
have a birth plan
 Patients with an allergic constitution or being allergic
to the study drug
 Mentally or legally disabled patients
 Patients who are participating in or have participated
in another drug clinical trial within the last 3 months
 Patients who have been judged by the investigator as
inappropriate to participate in the clinical trial.
Rejection criteria
 Misdiagnosis
 Not taking any study drug during the trial
 Using forbidden drugs or treatments during the trial
 No evaluable records after drug administration
Withdrawal criteria
 Worsening conditions during the trial, including a
body temperature higher than 39.0°C
 Experiencing anaphylaxis or serious adverse events
during the trial
 Quitting the clinical trial voluntarily
 The study drug is not taken as directed, or is taken
at doses <80% or >120% of the requirement
The study will be suspended early or terminated if any of
the following occur:
 Serious adverse event (SAE)
 The efficacy of the test drug is found to be poor or
even ineffective
 Flawed protocol or significant deviation from the
well-designed protocol
 The pharmaceutical supervisory and administrative
department decides to terminate the study for any
reason
 The sponsor decides to terminate the trial due to
management or funding problems
Interventions
Gantong Granules and placebo are provided and manu-
factured by Beikelian Pharmaceutical & Technology Co.,
Ltd, Shenzhen, China. Considering the characteristics of
Chinese herbal medicine, placebo is prepared by 10-fold
dilution of 5 g of Gantong Granules and then condensed
into granules. The minimum effective dose of Gantong
Granules is 5 g. After 10-fold dilution, the placebo will
not have any clinical or pharmacological effects. Placebo
is almost identical to the test drug in appearance, smelland taste. This preparation of placebo has been used in
herbal medicine trials in China and Japan. All drugs are
concealed in uniform packages with the same labels and
each package contains 5 plus 1 days’ dosage. Patients in
the high-dose group, medium-dose group, low-dose group
or placebo control group, will receive Gantong Granules
15 g, Gantong Granules 10 g plus placebo 5 g, Gantong
Granules 5 g plus placebo 10 g or placebo 15 g, respect-
ively. All drugs will be dissolved in 200 ml warm water and
taken orally before each meal 3 times daily for 3 to 5 days.
If all symptoms disappear within 3 days, the study drugs
should be taken for just 3 days; if not, for 5 days. During
the study, patients will be visited five times by the investi-
gators. The follow-up visits last for 7 days after the treat-
ment. Details of study procedures are shown in Figure 2.
Concomitant treatments and forbidden drugs
Patients will be allowed to continue using medications
for comorbidities, such as hypertension or diabetes. The
dosage, duration and name of any concomitant medica-
tion or treatment must be recorded carefully in the case
report form (CRF). When the body temperature of a par-
ticipant rises to higher than 39.0°C, physical cooling and/
or paracetamol can be used to reduce the fever. Any other
Western or Chinese therapy or medication that may affect
the study results is prohibited during the trial.
Outcome measures
Primary outcomes
The primary outcome of the study is the duration of all
symptoms, which is defined as the number of hours
from study enrollment to the time when the patient’s ill-
ness symptoms completely resolve. Each participant will
be instructed to record any changes in symptoms in the
patient diary, in which the data can be acquired. Investi-
gator will make an assessment of the duration based on
these data.
Secondary outcomes
Secondary outcomes include duration of primary symp-
toms and each symptom, time to fever relief and time to
fever clearance, change in TCM symptom score, and
change in Symptom and Sign Score.
Time to fever relief and time to fever clearance
In this study, all patients will be asked to record their
axillary temperature in the patient diary every 2 hours
within the first 24 hours; after that, if the temperature is
equal to or higher than 37.3°C, it should be recorded every
4 hours, and if the temperature is lower than 37.3°C, then
it should be recorded at 8 am. and 4 pm. every day. If the
temperature is below 37.3°C and no longer rises for
48 hours, subjects do not need to continue recording.
Time to fever relief is defined as the time from the first
Study Period
Enrollment Allocatiον Post-allocation Close-out
Visits Visit 1 Visit 2 Visit 3 Visit 4 Visit 5







Physical examination × × × ×








Clinical sign and symptom
score
× × × ×
Symptom duration × × ×
Routine blood test × × ×
Urinalysis × × ×
Liver function test × × ×
Renal function test × × ×
Electrocardiogram × × ×
Chest X-ray × × ×
Urine pregnancy test × × ×
Adverse event record × × ×
Others
Drug distribution ×
Drug recycling and count × ×
Figure 2 Study schedule for patients.
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0.5°C or to normal; time to fever clearance is defined as
the time from the first dose of the study drug until the
body temperature drops below 37.3°C and no longer rises
for 48 hours(calculated as the time to the start of the 48-
hour period).Change in TCM symptom score
The TCM symptom score system used in the study fol-
lows the Guidelines for Clinical Research of New ChineseMedicine [19], in which all symptoms are given graded
scores (Figure 3). TCM signs will also be assessed, but
not scored. The sum of all symptom scores is the cumu-
lative TCM symptom score. The change in cumulative
TCM symptom score is assessed by the percentage of
symptom score reduction (PSSR), which is calculated ac-
cording to the following formula:
PSSR ¼
 symptom score before treatment
‐symptom score after treatment




Primary 0 3 6 9
Fever and mild 
aversion
to cold
None 37.3-37.5 37.6-38 ≥38.1
Sore throat None Mild Moderate Severe
Secondary 0 1 2 3
Sore limbs None Mild Moderate Severe
Nasal congestion None Mild Moderate Severe
Nasal discharge None Mild Moderate Severe
Thirsty None Mild Moderate Severe
Cough None Seldom Occasionally Frequently
Cumulative
symptom score
Primary symptom scores + Secondary symptom scores





mucosa, pharynx palatine 
arches and uvula
With swelling and 
secretions
Total score All symptom scores +sign score
TCM sign
Tongue proper Red Others:
Tongue coating Thin and yellow Others:
Pulse condition Floating and rapid Others:
Figure 3 Symptom and Sign Scoring system.
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Pharyngeal hyperemia will be given graded scores as
common cold sign (Figure 3). The change in cumulative
Symptom and Sign Score is evaluated by the percentage
of Symptom and Sign Score reduction (PSSSR), which is
calculated according to the following formula:
PSSSR ¼
 symptom and sign score before treatment
‐symptom and sign score after treatment




Physical examination and some laboratory tests will
be performed both before and after treatment for safety
assessment. Physical examination includes temperature,
respiration, blood pressure, heart rate and weight. La-
boratory tests include routine blood test, urine analysis,
liver function test (ALT, AST, ALP, STB, and γ-GT),
renal function test (serum creatinine, microalbuminuria,
and serum cystatin C), and electrocardiogram. Beyond
that, before treatment, all subjects need to undergo a
chest X-ray, and female patients of childbearing age need
to take a urine pregnancy test.
Adverse event reporting
It is very important to ensure all patients’ safety during
the trial. Adverse events (AEs) should be recorded indetail on the adverse event form (AEF). All patients
experiencing an AE will be treated appropriately.
Regarding a SAE, the investigator must record it on the
SAE form, and it should be reported to the principal
investigator, CFDA, ethics committees and the sponsor
within 24 hours.
Quality control
All investigators are appropriately qualified by training
and experience to conduct and supervise the trial. The
principal investigator in each center will be responsible
for the implementation of the clinical trial which should
be in compliance with standard operation procedure.
Throughout this trial, specialized quality inspectors will
regularly review and monitor the experimental data from
CRFs every week. Monitoring results should be pre-
sented to the principal investigator. The inspector will
protect the privacy of the participants.
Data management
After review by the investigators and inspectors, com-
pleted CRFs will be sent to a specified statistics center,
where data entry and management will be completed by
two independent data administrators to ensure data ac-
curacy. All data will be managed by DAS (Direct At-
tached Storage) for electronic data management system.
To confirm the database, the principal investigator, the
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and make a statistical analysis plan. Finally, the data will
be locked and analyzed in accordance with the statistical
analysis plan.
Sample size calculation
Based on a previous clinical study [20], the mean duration
of all symptoms for the common cold was estimated to
be 7 days with a standard deviation of 3 days. Reduction
in the duration of all symptoms by 2 days is supposed
to be clinically relevant. Using Package for Encyclopedia
Medical Statistics (PEMS) 3.2 with 90% power and α = 0.05
(2-sided), the sample size needs to be 48 cases for each
group. Considering a drop-out of 20%, 60 subjects should
be recruited in each group. Consequently, the total sample
size is determined to be 240 patients.
Statistical analysis
The data analysis will be performed by professional stat-
isticians, in accordance with the statistical analysis plan
for this trial. The full analysis set (FAS) is the primary
analysis set for efficacy with an intention-to-treat (ITT)
principle. In the FAS, all patients will be treated with at
least one dose of the study drug and recorded with at
least one clinical observation in the study. All subjects
without any major protocol deviations will be involved
in per-protocol set (PPS). The safety analysis will be con-
ducted for randomized subjects who have completed at
least one study visit and have safety data. Descriptive statis-
tics will be performed on continuous variables, frequencies
and categorical variables. All symptom duration, primary
symptom duration, time to fever relief and time to fever
clearance will be estimated by the Kaplan-Meier technique
and be compared by the stratified log-rank test. Compari-
sons among groups will be conducted by an analysis of vari-
ance (ANOVA) and least significant differencet-test. In this
multicenter trial, the Cochran-Mantel-Haenszel test, strati-
fied by clinical centers, and the logistic regression model, ad-
justed for covariates, will be used. All data will be processed
by a professional statistician using SAS 9.2 software (SAS,
Cary, NC, USA), and a 2-sided P-value of < 0.05 is consid-
ered to be statistically significant.
Discussion
The common cold is something that one may experience
multiple times throughout his or her lifetime. To date, how-
ever, there is no well-proven treatment or cure for this dis-
ease. It is widely recognized that the randomized controlled
trial is a ‘gold standard’ methodology for evaluating the clin-
ical efficacy and safety of an intervention. Although Chinese
herbs have been widely used to treat the common cold in
China and many other countries, the quality of most prior
studies was assessed to be generally low due to methodo-
logical limitations like inadequate randomization, lack ofdouble blinding, non-placebo control, incomplete outcome
data, and so on [21,22]. So, there is a lack of robust evidence
to support the clinical utility of TCM treatment.
For the above reasons, this protocol is rigorously-designed
in accordance with the CONSORT (Consolidated Standards
of Reporting Trials) statement and SPIRIT (Standard Proto-
col Items: Recommendations for Interventional Trials) state-
ment [23,24]. As far as we know, this study will be the first
multicenter, double-blind, placebo-controlled and random-
ized clinical trial that is designed to treat CCWHS. Based on
scientific and objective assessment, this study will provide
high-quality evidence on the efficacy and safety of Gantong
Granules in treating CCWHS, and may help to optimize the
dose selection for a phase III clinical trial.
Trial status
The study is currently in the process of recruiting partici-
pants in the five trial centers.
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